Nappanee dairy farm used enrofloxacin and ceftiofur in calves contrary to labeling and kept incomplete treatment records.
What happened
FDA inspected the dairy operation on May 24, 2023, and June 21, 2023, and issued a Form FDA 483 (inspection observations). The letter says the farm did not respond to the 483 by Nov. 14, 2023. FDA found incomplete treatment records and use of enrofloxacin and ceftiofur in calves in ways not allowed by their labels, including no meat withdrawal for enrofloxacin and not following the labeled ceftiofur dose.
What FDA found
The farm did not keep complete treatment records for cattle and kept no treatment records for calves; the cattle records lacked dose, total days, route, and person medicating.
FD&C Act section 402(a)(4) [21 U.S.C. § 342(a)(4)]The farm gave enrofloxacin to calves for scours and respiratory disease by injection or orally, did not follow the meat withdrawal period, and used it in a class and for purposes not on the label.
21 CFR 530.41(a)(10)The farm used ceftiofur hydrochloride without following the labeled dose.
21 CFR 530.41(a)(13)(ii)Because the drugs were used outside their approved labeling and not under 21 CFR Part 530, FDA says the drugs were unsafe and adulterated.
FD&C Act section 501(a)(5) [21 U.S.C. § 351(a)(5)]
What FDA wants
Within 15 working days, notify FDA in writing of the specific steps taken to correct the violations and include related documentation. If corrections cannot be completed in that time, explain the reason for delay and when they will be completed.
Who should pay attention
- dairy farms that use enrofloxacin or ceftiofur in calves
- meat buyers sourcing from dairy farms
- veterinarians advising dairy producers on extralabel drug use
This is a summary. Read the original letter on fda.gov.